This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Radiographic Response
Timeframe: From baseline to preoperative imaging assessment after neoadjuvant therapy.
Pathologic Response
Timeframe: At the time of surgery, based on postoperative pathological evaluation.
Progression-Free Survival (PFS)
Timeframe: From the date of surgery until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.